Skip to main content
Erschienen in: Hepatology International 2/2022

26.03.2022 | Original Article

Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma

verfasst von: Rex Wan-Hin Hui, Albert Chi-Yan Chan, Gladys Lo, Regina Lo, Cura Chan, Clarence Nicholas Kotewall, Lung-Yi Mak, Wong-Hoi She, Kin-Pan Au, Victor Ai, James Fung, Man-Fung Yuen, Wai-Kay Seto

Erschienen in: Hepatology International | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Magnetic resonance (MR) elastography and proton density fat fraction (PDFF) are emerging techniques for non-invasive assessment of liver stiffness and steatosis, respectively. We investigated the role of MR metrics in pre-treatment prognostication of hepatocellular carcinoma (HCC).

Methods

Patients with newly diagnosed HCC were prospectively recruited. Pre-treatment MR elastography and PDFF were performed on tumor and non-tumor regions. HCC treatment was categorized as potentially curative (resection/ablation) or non-curative (locoregional/systemic therapy). HCC recurrence, liver-related complications (ascites/ variceal bleeding/ hepatic encephalopathy) and mortality were monitored.

Results

Of the 158 recruited patients (mean age 62.9 years, 84.2% male, 82.9% viral hepatitis), 58.2% (n = 92) and 41.8% (n = 66) received potentially curative and non-curative therapy, respectively. Pre-treatment non-tumor liver stiffness independently predicted liver-related complications, regardless of treatment type (HR 1.384, 95% CI 1.067–1.796, p = 0.014). In the potentially curative therapy group, non-tumor stiffness and non-tumor PDFF were independently associated with HCC recurrence (HR 1.308, 95% CI 1.022–1.673 & HR 1.080, 95% CI 1.009–1.156 respectively, both p < 0.05); and non-tumor PDFF predicted mortality (HR 1.160, 95% CI 1.038–1.296, p = 0.009). In the non-curative group, tumor stiffness independently predicted liver-related complications (HR 1.299, 95% CI 1.023–1.651, p = 0.032), and a combination of tumor stiffness ≥ 5.7 kPa plus non-tumor stiffness ≥ 3.7 kPa was associated with a two-fold risk of liver-related complications (86.7% vs 40.0%, p < 0.001).

Conclusion

Pre-treatment MR elastography and PDFF over tumor and non-tumor regions demonstrated prognosticating roles in HCC. Simultaneous measurements of both metrics during conventional MR liver should be considered in the diagnostic workup of HCC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249CrossRefPubMed
2.
Zurück zum Zitat Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6CrossRefPubMed Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6CrossRefPubMed
3.
Zurück zum Zitat Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338CrossRefPubMed Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338CrossRefPubMed
4.
Zurück zum Zitat Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–750CrossRefPubMed Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–750CrossRefPubMed
5.
Zurück zum Zitat Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289:816–830CrossRefPubMed Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289:816–830CrossRefPubMed
6.
Zurück zum Zitat Omata M, Cheng A-L, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hep Int. 2017;11:317–370CrossRef Omata M, Cheng A-L, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hep Int. 2017;11:317–370CrossRef
7.
Zurück zum Zitat Lee DH, Lee JM, Chang W, et al. Prognostic role of liver stiffness measurements using magnetic resonance elastography in patients with compensated chronic liver disease. Eur Radiol. 2018;28:3513–3521CrossRefPubMed Lee DH, Lee JM, Chang W, et al. Prognostic role of liver stiffness measurements using magnetic resonance elastography in patients with compensated chronic liver disease. Eur Radiol. 2018;28:3513–3521CrossRefPubMed
8.
Zurück zum Zitat Thomaides-Brears HB, Lepe R, Banerjee R, et al. Multiparametric MR mapping in clinical decision-making for diffuse liver disease. Abdom Radiol (NY). 2020;45:3507–3522CrossRef Thomaides-Brears HB, Lepe R, Banerjee R, et al. Multiparametric MR mapping in clinical decision-making for diffuse liver disease. Abdom Radiol (NY). 2020;45:3507–3522CrossRef
9.
Zurück zum Zitat Cho HJ, Kim B, Kim HJ, et al. Liver stiffness measured by MR elastography is a predictor of early HCC recurrence after treatment. Eur Radiol. 2020;30:4182–4192CrossRefPubMed Cho HJ, Kim B, Kim HJ, et al. Liver stiffness measured by MR elastography is a predictor of early HCC recurrence after treatment. Eur Radiol. 2020;30:4182–4192CrossRefPubMed
10.
Zurück zum Zitat Siripongsakun S, Lee JK, Raman SS, et al. MRI detection of intratumoral fat in hepatocellular carcinoma: potential biomarker for a more favorable prognosis. AJR Am J Roentgenol. 2012;199:1018–1025CrossRefPubMed Siripongsakun S, Lee JK, Raman SS, et al. MRI detection of intratumoral fat in hepatocellular carcinoma: potential biomarker for a more favorable prognosis. AJR Am J Roentgenol. 2012;199:1018–1025CrossRefPubMed
12.
Zurück zum Zitat Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–96CrossRefPubMed Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–96CrossRefPubMed
13.
Zurück zum Zitat Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85PubMed Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85PubMed
14.
Zurück zum Zitat Chan A, Zhang WY, Chok K, et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma: a changing paradigm in modulation of future liver remnant before major hepatectomy. Ann Surg. 2021;273:957–965CrossRefPubMed Chan A, Zhang WY, Chok K, et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma: a changing paradigm in modulation of future liver remnant before major hepatectomy. Ann Surg. 2021;273:957–965CrossRefPubMed
15.
Zurück zum Zitat Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699CrossRefPubMed Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699CrossRefPubMed
16.
Zurück zum Zitat Ohki T, Tateishi R, Shiina S, et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut. 2009;58:839–844CrossRefPubMed Ohki T, Tateishi R, Shiina S, et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut. 2009;58:839–844CrossRefPubMed
17.
Zurück zum Zitat Shinkawa H, Tanaka S, Takemura S, et al. Obesity and recurrence-free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C. Ann Gastroenterol Surg. 2018;2:319–326CrossRefPubMedPubMedCentral Shinkawa H, Tanaka S, Takemura S, et al. Obesity and recurrence-free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C. Ann Gastroenterol Surg. 2018;2:319–326CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Mak LY, Hui RW, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73:800–806CrossRefPubMed Mak LY, Hui RW, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73:800–806CrossRefPubMed
19.
Zurück zum Zitat Hui RWH, Seto WK, Cheung KS, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepatitis. 2018;25:97–104CrossRef Hui RWH, Seto WK, Cheung KS, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepatitis. 2018;25:97–104CrossRef
20.
Zurück zum Zitat Lallukka S, Sädevirta S, Kallio MT, et al. Predictors of liver fat and stiffness in non-alcoholic fatty liver disease (NAFLD)—an 11-year prospective study. Sci Rep. 2017;7:14561CrossRefPubMedPubMedCentral Lallukka S, Sädevirta S, Kallio MT, et al. Predictors of liver fat and stiffness in non-alcoholic fatty liver disease (NAFLD)—an 11-year prospective study. Sci Rep. 2017;7:14561CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Mathurin P, Beuzin F, Louvet A, et al. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther. 2007;25:1047–1054CrossRefPubMed Mathurin P, Beuzin F, Louvet A, et al. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther. 2007;25:1047–1054CrossRefPubMed
22.
Zurück zum Zitat Vos B, Moreno C, Nagy N, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastro-Enterol Belg. 2011;74:389–394 Vos B, Moreno C, Nagy N, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastro-Enterol Belg. 2011;74:389–394
24.
Zurück zum Zitat Bae JS, Lee DH, Yi NJ, et al. Magnetic resonance elastography versus transient elastography in the prediction of complications after resection for hepatocellular carcinoma. Ann Surg. 2020 Bae JS, Lee DH, Yi NJ, et al. Magnetic resonance elastography versus transient elastography in the prediction of complications after resection for hepatocellular carcinoma. Ann Surg. 2020
25.
Zurück zum Zitat Singh S, Fujii LL, Murad MH et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1573–1584.e1571–1572 (quiz e1588–1579) Singh S, Fujii LL, Murad MH et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1573–1584.e1571–1572 (quiz e1588–1579)
26.
Zurück zum Zitat Geethanath S, Vaughan JT Jr. Accessible magnetic resonance imaging: a review. J Magnet Resonance Imaging (JMRI). 2019;49:e65–e77CrossRef Geethanath S, Vaughan JT Jr. Accessible magnetic resonance imaging: a review. J Magnet Resonance Imaging (JMRI). 2019;49:e65–e77CrossRef
27.
Zurück zum Zitat Ling W, Lu Q, Lu C, et al. Effects of vascularity and differentiation of hepatocellular carcinoma on tumor and liver stiffness: in vivo and in vitro studies. Ultrasound Med Biol. 2014;40:739–746CrossRefPubMed Ling W, Lu Q, Lu C, et al. Effects of vascularity and differentiation of hepatocellular carcinoma on tumor and liver stiffness: in vivo and in vitro studies. Ultrasound Med Biol. 2014;40:739–746CrossRefPubMed
28.
Zurück zum Zitat Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69:1284–1293CrossRefPubMed Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69:1284–1293CrossRefPubMed
Metadaten
Titel
Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma
verfasst von
Rex Wan-Hin Hui
Albert Chi-Yan Chan
Gladys Lo
Regina Lo
Cura Chan
Clarence Nicholas Kotewall
Lung-Yi Mak
Wong-Hoi She
Kin-Pan Au
Victor Ai
James Fung
Man-Fung Yuen
Wai-Kay Seto
Publikationsdatum
26.03.2022
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 2/2022
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-022-10305-y

Weitere Artikel der Ausgabe 2/2022

Hepatology International 2/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.